ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).

Morihito Okada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.